415 related articles for article (PubMed ID: 27006304)
1. Vaccine adjuvants as potential cancer immunotherapeutics.
Temizoz B; Kuroda E; Ishii KJ
Int Immunol; 2016 Jul; 28(7):329-38. PubMed ID: 27006304
[TBL] [Abstract][Full Text] [Related]
2. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L
Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346
[TBL] [Abstract][Full Text] [Related]
3. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
4. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
Jahrsdörfer B; Weiner GJ
Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulatory oligonucleotides: ready for immunotherapy prime time!
Tam YK
J Hematother Stem Cell Res; 2003 Oct; 12(5):467-71. PubMed ID: 14594503
[No Abstract] [Full Text] [Related]
6. [Peptide vaccine therapy with TLR-9 agonist for patients with esophageal squamous cell carcinoma].
Katsuda M; Iwahashi M; Matsuda K; Miyazawa M; Nakamori M; Nakamura M; Naka T; Ojima T; Iida T; Yamaue H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1942-4. PubMed ID: 22202246
[TBL] [Abstract][Full Text] [Related]
7. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo.
Linghua Z; Xingshan T; Fengzhen Z
Int Immunopharmacol; 2006 Aug; 6(8):1267-76. PubMed ID: 16782539
[TBL] [Abstract][Full Text] [Related]
9. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
Kobiyama K; Ishii KJ
Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159
[TBL] [Abstract][Full Text] [Related]
10. Targeting CpG Adjuvant to Lymph Node via Dextran Conjugate Enhances Antitumor Immunotherapy.
Zhang W; An M; Xi J; Liu H
Bioconjug Chem; 2017 Jul; 28(7):1993-2000. PubMed ID: 28644608
[TBL] [Abstract][Full Text] [Related]
11. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
12. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
[TBL] [Abstract][Full Text] [Related]
13. MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses.
Taylor D; Meyer CT; Graves D; Sen R; Fu J; Tran E; Mirza B; Rodriguez G; Lang C; Feng H; Quaranta V; Wilson JT; Kim YJ; Korrer MJ
Front Immunol; 2022; 13():936129. PubMed ID: 36059502
[TBL] [Abstract][Full Text] [Related]
14. DNA-based immunotherapeutics for the treatment of allergic disease.
Horner AA; Van Uden JH; Zubeldia JM; Broide D; Raz E
Immunol Rev; 2001 Feb; 179():102-18. PubMed ID: 11292014
[TBL] [Abstract][Full Text] [Related]
15. New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA.
Creticos PS; Chen YH; Schroeder JT
Immunol Allergy Clin North Am; 2004 Nov; 24(4):569-81, v. PubMed ID: 15474859
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
Banday AH; Jeelani S; Hruby VJ
Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
[TBL] [Abstract][Full Text] [Related]
17. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments.
Cuzzubbo S; Mangsbo S; Nagarajan D; Habra K; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():615240. PubMed ID: 33679703
[TBL] [Abstract][Full Text] [Related]
18. STING-mediated DNA sensing in cancer immunotherapy.
Zhou X; Jiang Z
Sci China Life Sci; 2017 Jun; 60(6):563-574. PubMed ID: 28639100
[TBL] [Abstract][Full Text] [Related]
19. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives.
Francis JN; Durham SR
Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):543-8. PubMed ID: 15640697
[TBL] [Abstract][Full Text] [Related]
20. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
